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 1 
Preliminary data of this report were presented as oral presentation at the XXV Congress of the 2 
International Society on Thrombosis and Haemostasis, June 20th to 25th, Toronto, Canada  3 
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Abstract 1 
Background: Frequent arterial and venous thromboembolism in patients with congenital 2 
afibrinogenemia (CA) is neither understood nor is a safe and effective treatment established.  3 
Objectives: To report on the clinical observations and laboratory data contributing to the 4 
understanding of the frequency, physiopathology, prognosis and treatment of CA. 5 
Patients/Methods: We observed the long-term clinical course and laboratory data in a cohort of 6 
four patients with CA and thromboembolic complications, and conducted a systematic review 7 
retrieving all available data.  8 
Results: Four patients with CA developed recurrent and extensive arterial and venous 9 
thromboembolism (TE) from an age of 25–38 years. In two patients, a treatment strategy 10 
targeting at maintaining constantly measurable Fbg levels (≥0.5 g/L) either by regular Fbg 11 
replacement or by orthotopic liver transplantation resulted in long-term remissions. Radiological 12 
imaging documented resolved arterial thrombi after 6–12 months. In contrast, recurrent 13 
thromboembolic events were observed in two other patients with infrequent Fbg replacement. A 14 
systematic review of the literature revealed 48 reports of TE in patients with CA (median age at 15 
first event 31 years), and a favorable outcome in most patients with frequent application of Fbg, 16 
aimed at constant measurable trough levels.  17 
Conclusions: Present data suggests that patients with CA are at high risk of arterial and venous 18 
thromboembolic events, probably caused by thrombin excess owing to lack of thrombin 19 
scavenging by Fbg/fibrin. Regular low-dose Fbg replacement might be a safe and effective 20 
treatment option in patients with CA and thromboembolic complications. 21 
Keywords:  22 
Afibrinogenemia, venous thromboembolism, thrombosis, aortic disease, arterial occlusive 23 
disease, peripheral vascular disease, fibrinogen 24 
  25 
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Introduction 1 
Congenital afibrinogenemia (CA) is a rare disorder with a high risk of severe bleeding 2 
complications. Paradoxically, thromboembolic (TE) events have also been reported in affected 3 
patients. Fibrin and its precursor fibrinogen (Fbg) have a central role in hemostasis. Thrombin is 4 
the key procoagulant enzyme [1], converting the soluble glycoprotein Fbg into fibrin monomers, 5 
which spontaneously form polymers that are cross-linked by factor XIIIa to form an insoluble 6 
and stable fibrin plug. Furthermore, thrombin stimulates inhibitors of fibrinolysis, such as alpha-7 
2-antiplasmin, plasminogen activator inhibitor-1 (PAI-1) and thrombin activatable fibrinolysis 8 
inhibitor (TAFI) [2]. It is difficult to understand how a complete lack of Fbg is consistent with 9 
life.  10 
While bleeding problems can be effectively treated with Fbg concentrates, management of 11 
thromboembolic events is difficult and recommendations for CA patients are lacking. CA is 12 
defined as a total absence of circulating Fbg [3]. In all the CA cases studied to date, homozygous 13 
or compound heterozygous mutations have been found within one of the three Fbg genes (FGA, 14 
FGB, FGG) on chromosome 4q28 encoding the Fbg polypeptide chains (Aα, Ββ, γ) [4]. More 15 
than 100 patients with CA have been described and although CA is primarily regarded as a 16 
bleeding disorder [3, 5], in a number of cases venous and arterial thromboembolic complications 17 
have also been reported. While most authors blame Fbg replacement or the presence of 18 
thrombophilic risk factors for these complications, others regard CA itself as a cause of 19 
thromboembolism [4].  20 
To contribute to this discussion, we report on the long-term clinical course and laboratory data in 21 
a cohort of four CA patients with severe thromboembolic complications. In addition, we 22 
conducted a systematic review retrieving all available data on patients with CA and 23 
thromboembolic complications.  24 
Materials and Methods 25 
Patients and follow-up 26 
Four CA patients treated in our institution between 1960 and 2015 were included in this study.  27 
Casuistic presentations focus on patients A2, A3 and B1, who were treated predominantly in our 28 
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hospital, while the history of patient A1, treated mainly elsewhere, and an additional patient, A4, 1 
is discussed only briefly.  2 
The patients were followed in our outpatient unit on a regular basis. The number of visits varied 3 
from three times a week in critical situations to once in 6 to 12 months during asymptomatic 4 
periods. All patients gave informed consent and approval for the publication of their cases. The 5 
study was conducted in accordance with Swiss regulations and the Declaration of Helsinki 6 
(1996). Ethical approval was not required. 7 
Data collection 8 
Clinical and laboratory data were systematically recorded in the hospital database and patient 9 
charts; responsible physicians entered health related information on every visit. Magnetic 10 
resonance imaging (MRI) and computed tomography (CT) scans obtained over the past 15 years 11 
were stored electronically. The following clinical data were pseudonymized and transferred to 12 
the study database: number, type, severity and circumstances of bleeding events; number, type, 13 
severity and circumstances of thromboembolic (TE) events; dosage, interval and type of 14 
treatment (Fbg replacement, anticoagulant treatment, platelet inhibitors, interventions); outcome 15 
of treatment. Additionally, we contacted responsible physicians, requested patient reports and 16 
asked patients to complete a questionnaire regarding bleeding and TE episodes, treatment and 17 
involved physicians and institutions. 18 
Laboratory analyses 19 
The following laboratory data were recorded: functional Fbg plasma levels (peak and trough; 20 
Clauss method), Fbg antigen levels, D-dimers, prothrombin fragment F1+2, thrombin-21 
antithrombin complexes (TAT), prothrombin time, activated partial thromboplastin time, platelet 22 
aggregation and platelet flow cytometry studies. Even though coagulation analyzers, reagents 23 
and assay details changed several times between 1960 and 2015, the methodological principles 24 
remained the same. All laboratory analyses were performed at the University Clinic of 25 
Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, 26 
Switzerland, which is accredited by the Swiss Accreditation Service (SAS). Functional Fbg 27 
levels were determined by the Clauss method [6]. In plasma samples with a Fbg level < 0.75 g/L, 28 
concentration was determined using a manual method. Underlying mutations in fibrinogen genes 29 
were identified as previously described [7].  30 
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Systematic review 1 
MEDLINE and EMBASE databases were searched for publications reporting venous and arterial 2 
thromboembolic complications in patients with CA. A search strategy was developed (see 3 
supplemental data) and tested in a set of 6 index publications (100% sensitivity). The literature 4 
search was supplemented by a manual review of the reference lists in identified publications. No 5 
restrictions regarding language or publication date nor formal requirements for diagnosis of CA 6 
were applied. In case patients were reported more than once, only the most comprehensive 7 
publication was included. We did not include a previous publication on patient A2 of our case 8 
series [8]. No quality assessment was conducted as quality was expected to be low and an 9 
established quality assessment tool for case reports does not exist.  The literature search was last 10 
updated on May 5th 2015. The following data were extracted: author/year, results of molecular 11 
analysis, age at first TE symptoms, type of thromboembolic complication, treatment (type, dose 12 
and interval of Fbg replacement and anticoagulation therapy), outcomes and observation period.  13 
Results 14 
Patients 15 
Four patients with CA and TE were treated between 1960 and 2015 in our institution: two 16 
brothers (A1, A2), their male cousin (A3) and one unrelated female patient (B1). An additional 17 
patient (A4; brother of A3) did not experience TE. All five patients were homozygous for a large 18 
11kb deletion of the fibrinogen alpha gene (FGA), which according to haplotype analysis had 19 
occurred on four distinct ancestral alleles [9, 10]. A summary of the clinical characteristics, 20 
treatment and outcomes is given in Table 1, details are provided below.  21 
Patient A2 22 
The 53-year-old male patient A2 experienced severe bleeding events already in childhood: 23 
multiple skin and gingival bleedings, extensive muscle hematomas, joint bleeding, and a major 24 
intracranial hemorrhage. Fbg was replaced weekly. At the age of 38, he suffered a major stroke 25 
due to a thromboembolic occlusion of the left middle cerebral artery. A large floating thrombus 26 
was documented in the aortic arch and the thoracic aorta (Figure 1). Even though low molecular 27 
weight heparin (LMWH) and aspirin 100 mg were given, additional TE events occurred: 28 
recurrent splenic and renal infarctions, ischemic necrosis of toes, paralytic ileus, thrombosis of 29 
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subclavian vein, and recurrent ischemic strokes. Eventually, liver transplantation was considered 1 
the only remaining option and at the age of 44 years, the patient underwent successful orthotopic 2 
liver transplantation [8]. The last Fbg replacement was applied before and during surgery (6 g), 3 
and since then Fbg plasma levels remained above 2.5 g/L. The aortic thrombus nearly 4 
disappeared (Figure 1) and no further TE or bleeding events occurred after the liver 5 
transplantation ten years ago.  6 
Patient A3 7 
The clinical course of the currently 50-year-old male patient A3 is illustrated in Figure 2 [11]. 8 
Severe bleeding events occurred already in childhood and prophylactic treatment was initiated (2 9 
g Fbg weekly to monthly). At the age of 25 years, a deep vein thrombosis and extensive 10 
pulmonary embolism occurred several days after surgery for a hip fracture despite prophylactic 11 
heparin treatment while receiving Fbg replacement. During subsequent years, the patient 12 
experienced cerebral vein thrombosis and recurrent pulmonary embolism. A possible TE trigger 13 
was identified for some events (postoperative period, infection, Fbg replacement), but not in 14 
others. At the age of 43 years, following a mild upper respiratory infection, acute ischemia of 15 
digits I to IV of the right hand occurred and a large thrombus in the brachiocephalic trunk and 16 
the left subclavian artery was documented (Figure 3). Despite prophylactic LMWH treatment, 17 
multiple and recurrent cerebral infarctions developed. An intensified treatment scheme was 18 
developed consisting of frequently administered, low-dose Fbg replacement aimed at 19 
maintaining measurable Fbg levels with trough values of ≥ 0.5 g/L and avoiding high peak 20 
values. Initially, 1 g was given daily (patient weight 74 kg). Currently the patient administers 21 
Fbg every three to four days (1 and 2 g, respectively, weekly dose 3g). Additionally, aspirin 100 22 
mg and prophylactic doses of LMWH was given during the first year. Since implementation of 23 
this regimen eight years ago, no further TE or major bleeding events have occurred. MR imaging 24 
five months after intensified treatment revealed nearly complete regression of the arterial 25 
thrombi (Figure 3). 26 
Patient B1 27 
The 48-year-old female patient suffered from mild to moderate bleeding during childhood and 28 
adolescence. At the age of 30 years, she experienced massive pulmonary embolism while 29 
suffering from pneumonia and following a blunt thoracic trauma, needing Fbg replacement (2 g 30 
Nagler, M. et al. Thromboembolism in congenital afibrinogenemia      8 / 26 
daily; body weight 75 kg). Pulmonary embolism reoccurred despite daily application of fresh, 1 
frozen plasma supplemented with prophylactic-dose LMWH. However, the patient preferred to 2 
remain on Fbg concentrates every two weeks rather than to switch to a frequently administered, 3 
low-dose application as used in patient A3. A growing thrombus occluding the right main 4 
pulmonary artery and extending into the left pulmonary artery with multiple small pulmonary 5 
emboli into the left lung were diagnosed in 2015. An intensified treatment aimed at Fbg trough 6 
levels of ≥ 0.5 g/L (while avoiding high peak values) and anticoagulation with apixaban (2 x 2.5 7 
mg daily) was initiated.  8 
Patient A1 was born in 1960. He suffered from a stroke with multifocal cerebral ischemia due to 9 
occlusion of the left vertebral artery at the age of 51. While receiving treatment with 1 x 3 g Fbg 10 
per week supplemented with 100 mg aspirin (body weight 74 kg), he experienced further 11 
thromboembolic events: myocardial infarction, pulmonary embolism and occlusion of the right 12 
iliac artery. At present, patient A1 is not treated in our institution and intensified treatment with 13 
twice weekly Fbg replacement was not implemented. 14 
Other causes for TE could not be identified. The father of patient A3 experienced myocardial 15 
infarction at 50 years of age and the mother of A1/A2 suffered from coronary heart disease. 16 
Laboratory studies 17 
In all patients, Fbg plasma concentrations were below the detection limit of the Clauss method 18 
and were not measurable immunologically. Prothrombin time and activated partial 19 
thromboplastin time were not clottable. No anti-Fbg antibodies have been detected in any of the 20 
patients. An extensive panel of thrombophilia markers was negative in all patients except for 21 
patient B1, who was found to be a heterozygous carrier of the prothrombin G20210A mutation.  22 
TAT complexes were assessed before Fbg administration on 49 occasions (patients A2, A3 and 23 
B1) as well as before and after Fbg administration on 18 occasions, and were increased in 90% 24 
of cases (mean 19.5 µg/L; SD 15.9; normal <4.1 µg/L). Administration of Fbg resulted in a 25 
decrease of TAT levels in all but two instances (p = 0.008; Figure 4A). Without Fbg 26 
replacement, D-dimers were < 45 µg/L (detection limit) at all-time points. After treatment, D-27 
dimers increased to normal values (Figure 4B). Changes of hemostatic parameters upon Fbg 28 
replacement for patient A3 (most complete records) are shown in Table 2. 29 
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Systematic review 1 
The literature search yielded 599 records including 5 publications identified by manual review 2 
(see PRISMA flow chart, Figure S1 supplemental data). After removal of duplicates, titles and 3 
abstracts of 537 records were screened, and 94 publications were selected for full-text review. 4 
Finally, we included 46 studies reporting on 48 patients with CA and TE complications. Details 5 
of the patients are reported in Table 3. A wide range of venous and arterial TE complications 6 
were reported, covering not only common (such as pulmonary embolism) but also rare 7 
manifestations (spinal cord infarction). A cluster of aortic thrombi and ischemic necrosis of toes 8 
and fingers is discernable. At the time of the first TE event, patients were at young age (median 9 
31 years, range 0 to 48, mean 29.6). Treatment strategies varied widely though details of dosage 10 
and timing were often not provided. In addition, the effects of treatment are difficult to appraise 11 
because the observation period was usually short. However, treatment comprised frequent 12 
applications of Fbg aimed at maintaining Fbg levels above a certain threshold in 11 patients [12-13 
22]. The reported outcome was favorable in all but one [21] of these patients. 14 
Discussion 15 
Key findings 16 
Extensive venous and arterial thromboembolism was observed frequently in patients with CA, 17 
both in our cohort of four patients and also in published reports. Frequent Fbg replacement with 18 
target trough levels of ≥0.5g/L or orthotopic liver transplantation permitted anticoagulant and/or 19 
antiplatelet therapy supporting resolution of arterial and venous thrombi, and effectively 20 
prevented further TE events, which in contrast, were not prevented in patients with infrequent 21 
and sporadic Fbg replacement. It seems likely that regulation of generated thrombin is enhanced 22 
by the permanent presence of Fbg as reflected by decreased TAT-levels upon Fbg replacement 23 
(Figure 4). Systematic review identified 48 reports of patients with CA and often severe TE, 24 
which occurred at young age. Treatment schemes aimed to maintain Fbg levels above a certain 25 
threshold resulted in favorable outcomes in all but one of 11 patients. 26 
Comparison with other studies 27 
The present investigation expands previous case reports and laboratory studies, which are 28 
essentially in line with our results. TE complications in CA patients reported in the literature 29 
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were identified by the systematic review [5, 12-55]. Even though many details of treatment 1 
schemes and outcomes were not described, frequent Fbg administration aiming at maintaining 2 
trough Fbg levels above a certain threshold were apparently successful in 10 patients [12-20, 22]. 3 
Several authors observed elevated markers of thrombin formation in CA patients’ plasma, as we 4 
did: TAT complexes [31, 53], thrombin generation [31, 56] and prothrombin fragments F1+2 5 
[31, 57] were often increased. Following Fbg replacement, these markers usually decreased. 6 
Reduced levels of D-dimers were also observed in a study by Korte et al. [57] and were corrected 7 
by Fbg replacement. 8 
Strengths and limitations 9 
Our investigation has limitations. As is typical for ultra-rare diseases we are restricted to a case 10 
series rather than to a prospective cohort study or a randomized controlled trial. However, four 11 
out of our five patients experienced severe and recurrent arterial and venous TE events from a 12 
young age. In addition, we identified 48 patients with TE complications through a systematic 13 
review of the literature further supporting an association between CA and TE risk. Similarly, 14 
treatment effects have not been studied in a randomized controlled trial applying standardized 15 
interventions and pre-specified outcome definitions. Again, given the rarity of the disease, this is 16 
unlikely to be possible in the near future. The clinical course of our four patients as well as the 17 
reports identified in the literature suggest that TE events re-occur frequently in inadequately 18 
substituted patients. In contrast, in our two patients (A2 and A3) after establishing Fbg trough 19 
levels ≥ 0.5g/L, no further TE events occurred during subsequent follow-up of 7 and 9 years, 20 
respectively, which is in line with a number of reports successfully employing similar 21 
replacement schemes.  22 
As another limitation, we are not able to draw conclusions on two important questions: (1) is 23 
there an association between Fbg replacement and the occurrence of TE events, and (2) how 24 
shall we treat TE events initially. Patients showed up several hours or even days after the onset 25 
of symptoms and Fbg plasma levels were not systematically determined. Some events occurred 26 
in the course of an intensified treatment (eg. postoperatively, or after hemorrhage) suggesting 27 
Fbg replacement to be a potential contributor. However, other events occurred several days or 28 
even weeks after last Fbg application when plasma levels were already below detection limit, 29 
suggesting other triggers as well. The same holds for the initial treatment of TE. We treated the 30 
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patients over a time-period of several decades. The dosage and time-interval of Fbg concentrates 1 
as well as anticoagulants and platelet inhibitors varied widely and depended on a large number of 2 
factors, the presence of bleeding complications in particular. 3 
The strength of our report is that we treated several patients and observed their long-term 4 
outcomes over many years.  5 
Implications for clinical practice 6 
We believe that CA must not only be perceived as a bleeding disorder but as a major 7 
thromboembolic risk factor, in particular with increasing patient age. Medical care should not 8 
only focus on treatment and prevention of bleeding complications, but also on the prevention of 9 
(recurrent) TE events, especially as patients get older. Even though many events occur without 10 
triggers, the risk appears to be higher in situations with coagulation activation, such as infections, 11 
interventions or trauma. Frequently administered, low-dose Fbg replacement to maintain Fbg 12 
levels of at least 0.5 g/L is a promising strategy for the treatment and prevention of TE 13 
complications.  14 
Pathophysiology of thrombus formation in CA patients 15 
It is still unclear how patients with CA form thrombi. We observed increased levels of TAT 16 
complexes, which were normalized following Fbg administration. This observation is in line 17 
with studies demonstrating increased thrombin generation in patients with CA [31, 53, 56, 57]. 18 
The most likely reason for increased thrombin generation is impaired clearance and sequestration 19 
of thrombin by missing Fbg/fibrin [4, 56, 58] which was shown to have an antithrombin activity 20 
(formed fibrin: Antithrombin I [56, 58]). Excess thrombin might not only activate endothelial 21 
cells [59] but also platelets that may aggregate in the presence of von Willebrand factor even in 22 
the absence of Fbg [60]. Indeed, in fibrinogen knockout mice, platelet deposition upon vessel 23 
wall injury was similar to wild-type mice and thrombi grew very efficiently; the formed thrombi, 24 
however, were not stable, often ripped off the vessel wall leading to the downstream vessel 25 
occlusions [61]. Enlarged and loosely packed thrombi were also observed in the blood of CA 26 
patients under flow conditions in vitro [62].  27 
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Conclusions 1 
In conclusion, our data indicate that patients with CA are at high risk of arterial and venous 2 
thromboembolic events. Our data provide further evidence of an antithrombotic effect of 3 
Fbg/fibrin in-vivo and suggests frequent, low-dose Fbg replacement therapy to be a safe and 4 
effective treatment option in CA patients with thromboembolic complications. 5 
  6 
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Tables 1 
Table 1: Characteristics of four patients with congenital afibrinogenemia and thromboembolic 2 
events 3 
Patient Sex Year 
of 
birth 
Age at first 
TE 
symptoms 
Thromboembolic 
complications 
Bleeding events Long-term 
treatment 
Outcomes 
(observation 
period) 
A1 male 1960 51 Recurrent ischemic stroke 
Major myocardial infarction 
Bilateral pulmonary embolism 
Peripheral artery disease 
Joint bleedings 
Extensive muscle 
bleedings 
1x3 g Fbg / 
week 
Recurrent TE 
events 
A2 male 1962 38 Amaurosis fugax 
Major thrombus aortic arch 
Recurrent ischemic stroke 
Recurrent splenic infarction 
Renal infarction 
Upper extremity deep vein 
thrombosis 
Superficial vein thrombosis 
Ischemic necrosis of toes 
Recurrent intracranial 
hemorrhage 
Extensive muscle 
bleedings 
Multiple hematomas 
Gingival bleedings 
Ankle joint bleeding 
 
Orthotopic 
liver 
transplantati
on (OLT) 
No TE in the 9 
years following 
OLT  
A3  male 1965 25 Recurrent pulmonary 
embolism 
Deep vein thrombosis 
Cerebral vein thrombosis 
Recurrent ischemic stroke 
Arterial occlusion right hand 
Thrombosis subclavian artery 
Ischemic necrosis of toes and 
fingers 
Umbilical cord 
bleeding 
Subdural hematoma 
Intracerebral 
hemorrhage 
Joint bleedings 
Extensive muscle 
hematomas 
Multiple skin bleedings 
1x2g, 1x1g 
Fbg / week 
Aspirin 
100mg/d 
No TE event 
recorded in 7 
years 
B1 female 1967 30 Massive, recurrent pulmonary 
embolism 
Extensive thromboembolism 
of both pulmonary arteries 
Perfusion disorder of fingers 
and toes 
Umbilical cord 
bleeding 
Joint bleedings 
Recurrent hemoptysis 
Extensive pleural 
bleedings 
Gingival bleedings 
Extensive muscle 
bleedings 
Menorrhagia 
2x2 g Fbg /  
week 
Apixaban 
2.5mg 2x/d 
No recurrent 
event since 
Fbg/apixaban 
9 months ago 
 4 
  5 
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Table 2: Hemostatic parameters before and after replacement of 2g fibrinogen concentrate 1 
(patient A3; body weight 74 kg) 2 
Parameter Before treatment* Effects of prophylactic treatment† 
Prothrombin time (%) incoagulable 30 to 50* 
Activated partial thromboplastin time (s) incoagulable 35 to 40*# 
Plasma fibrinogen level (g/L)
 ‡
 not detectable 0.5 to 0.7* 
D-dimer levels (µg/L) < 45* 100 to 200* 
Thrombin-antithrombin complex (µg/L) 19.5 (15.9)
§
 1.5 to 5.0* 
* approximate values; † peak-level; ‡ Clauss’ method; § mean (SD) 3 
  4 
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Table 3: Reports of afibrinogenemia patients with thromboembolic events, treatment and outcome – a systematic review. 
Author, year Age* Sex Molecular analysis Type of complication Treatment Outcomes  
(observation period) 
Bas 2009 [23] 22 Female - Spinal cord infarction Fibrinogen replacement Neurological improvement (4 
months) 
Berkouk-Redjimi 
2014  [24]  
(two patients)
 †
 
- - - Type of TE not stated - - 
Bornikova 2011 
[25] 
- - Heterozygous mutation 
in FGG gene 
Type of TE not stated - - 
Boukhris 2014 
[26] 
- - - Digital necrosis - - 
Casini 2014 [63] 30 Male Homozygous mutation 
in FGB gene 
Pulmonary embolism Low molecular weight heparin Symptomatic pulmonary 
hypertension 
Castaman 2009 
[12] 
35 Female Homozygous mutation 
in FGG gene 
Renal artery occlusion 2 g fibrinogen every second day Partial lysis of thrombus (10 
days) 
Chapin 2013 
[13] 
33  Female Homozygous mutation 
in FGA gene 
Pulmonary embolism 
Catheter-related thrombosis 
Bi-weekly fibrinogen replacement 
LMWH 
Resolution of PE (4 month) 
Chevalier 2011 
[27] 
37 Male Compound 
heterozygous mutation 
in FGA gene 
Recurrent deep vein thrombosis 
Cerebral vein thrombosis 
Pulmonary embolism 
Inferior vena cava thrombosis 
Changing doses of fibrinogen, LMWH/ UFH Death 
Chun 2005 [14] 22 Male - Internal carotid artery occlusion 
(cerebral infarction) 
Myocardial infarction 
Catheter thrombosis 
Fibrinogen (target 0.8 to 1.5 g/L) Improvement (3 weeks) 
Dear 2006 [29] 34 Male Homozygous intronic 
mutation in FGB gene 
Cerebral infarction 
Myocardial infarction 
- - 
Dupuy 2001 [31] 30 Male - Ischemic lesions of toes 
Stenosis of iliac artery 
 
Bypass operation, fibrinogen, LMWH, Aspirin Clinical improvement, bypass 
occlusion (three weeks) 
Erlacher 2009 
[15] 
20 Male Homozygous mutation 
in FGA gene 
Digital ischemic necrosis Fibrinogen replacement for 7 weeks (initially daily) Clinical improvement (7 
weeks) 
Falsoleiman 
2012 [32] 
30 Female - Myocardial infarction Antiplatelet therapy, angioplasty, bare metal stent Recurrent event (one year) 
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Fuchs 2007 [33] 20 Female Homozygous mutation 
in FGG gene 
Budd-Chiari syndrome 
Inferior vena cava thrombosis, 
ommon iliac vein thrombosis 
Liver transplantation Successful transplantation 
Garcia-Monco 
1996 [34] 
28 Female - Medullary infarction due to 
vertebral artery dissection 
Fibrinogen replacement, UFH, warfarin Improvement (1 year) 
Girard 2005 [35] 41 Female - Ischemic necrosis of toes Plasma exchange and fibrinogen replacement every 6 
weeks 
Improvement (13 months) 
Goudier 2007 
[36] 
20 Female - Ischemic necrosis of toes Surgical amputation, reduction of monthly fibrinogen 
replacement 
Recurrence 
Grandone 2012 
[37] 
36 Male Homozygous mutation 
in FGB gene 
Ischemic stroke 
Thrombosis right radial artery 
Fibrinogen replacement (target trough levels >1.5 g/L) - 
Haberer 2008 
[38] 
30 Female - Postoperative deep vein 
thrombosis 
Compression stocking Stable complaints (9 days) 
Hanano 1992 
[39] 
37 Female - Ischemic necrosis of toes - - 
Jimenez 
Caballero 2006 
[40] 
46 Female - Pulmonary embolism - - 
Karim 2011[16] Newborn Female - Sinus cerebral thrombosis 
Internal jugular vein thrombosis 
Fibrinogen replacement 3 times a week, LMWH Recanalization (4 months) 
Katsinelos [41] 22 Female - Intestinal ischemia - - 
Kinebuchi 2002 
[17] 
30 Male - Leg ulcer due to suspected 
recurrent DVT 
Fresh frozen plasma Wound healing (2 months), 
reoccurrence after discharge 
Kumar 2008 [42] 27 Male - Myocardial infarction Aspirin, clopidogrel Improvement (two days) 
Lak 1999 [5] 14 Female - Gangrene foot due to thrombotic 
popliteal occlusion 
Amputation - 
 5 Male - Sinus vein thrombosis - - 
Laufs 2004 [18] 32 Female - Spinal cord infarction due to 
vertebral artery occlusion 
Fibrinogen replacement (target trough levels >0.8 g/L) Improvement, recanalization of 
vertebral artery 
Lebreton 2015 
[43] 
32 Female Homozygous mutation 
in FGA gene 
Heterozygous factor V 
Leiden mutation 
Pulmonary embolism 
Deep vein thrombosis 
Fibrinogen replacement every second day, 
intermediate-dose LMWH 
- 
MaKinnon 
1971[44] 
36 Female - Gangrene foot 
Aortal thrombus 
Initially fibrinogen replacement Improvement of gangrene, 
died 18 month later 
Matsumoto 2008 35 Female - Catheter-related thrombosis Fibrinogen replacement (initially every second day), Improvement (6 months) 
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[19] Pulmonary embolism UFH, warfarin 
Molho-Sabatier 
1991 [45] 
33 Female - Ischemic necrosis of toes due to 
iliac artery thrombosis 
- - 
Moscardo 2014 
[46] 
32 Female - Ischemic necrosis of toes and 
fingers 
Aspirin, LMWH Mild improvement (observation 
period not stated) 
Oruc 2006 [47] 16 Female - Budd-Chiari syndrome No treatment Death 
Ozdemir 2015 
[64] 
23 Female - Ischemic necrosis of toes and 
upper extremity venous 
thrombosis 
LMWH, aspirin, nifedipine, fibrinogen replacement - 
Pati 2009 [48] 32 Female - Pulmonary embolism 
Thrombosed vena cava inferior 
No treatment - 
Roque 2004 [49] - Female - Placental infarctions  
Renal vein thrombosis 
Cryoprecipitate, LMWH Recanalization (27 days) 
Rupec 1996 [50] - - - Ischemic necrosis of toes - - 
Sakai 2011 [51] 34 Female - Spinal cord infarction due to 
vertebral artery occlusion 
- - 
Santoro 2015 
[52] 
36 Male Compound 
heterozygous mutation 
in FGA gene 
Lower limb arterial thrombosis LMWH, fibrinogen replacement, iloprost Progressing arterial 
thrombosis, amputation 
Sartori 2012 [20] 48 Female - Aortic thrombosis 
Ischemic necrosis of toes 
Fibrinogen replacement (target trough levels >0.8 
g/L), prophylactic dose LMWH, Aspirin 
Improvement, recanalization of 
aortic thrombus (6 month) 
Schuepbach 
2004 [53] 
44 Male Homocygous mutation 
in FGA gene 
Lower limb arterial thrombosis Angioplasty, prophylactic dose LMWH/UFH/lepirudin, 
fibrinogen replacement (target through levels > 0.5 
g/L) 
Recurrent events 
Simsek 2008 
[54] 
20 Male Homozygous mutation 
in FGA gene 
Deep vein thrombosis 
Ischemic digital necrosis 
Pulmonary embolism 
Thrombus subclavian artery 
Ischemic stroke 
Prophylactic LMWH, intercurrent iloprost and fresh 
frozen plasma, intercurrent Aspirin 
Recurrent events 
Takasugi 2005 
[55] 
19 Male - Mesenteric vein thrombosis 
 
Small intestine resection - 
Taslimi 2011 
[21] 
27 Female - Mesenteric and portal vein 
thrombosis 
UFH, fibrinogen replacement (target trough levels 0.5 
to 1 g/L), small intestine resection 
Death 2 days postoperatively 
Teresa 2015 
[22] 
48 Female - Ischemic necrosis of toes 
Thrombus of abdominal aorta 
Fibrinogen replacement (initially target trough levels 
>0.8 g/L, later on >0.4 g/L), prophylactic dose 
LMWH/fondaparinux, Aspirin 
Full recovery of necrosis, 
resolution of aortal thrombus 
(two years) 
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Vu 2003 [65] 0.5 Male Compound 
heterozygous mutation 
in FGB gene 
Upper extremity venous 
thrombosis 
Fibrinogen replacement No recurrent event (four years) 
† no further information provided; * at first TE symptoms
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Extra table 
What is known about this topic? • Thromboembolism has been reported in patients with congenital 
afibrinogenemia (CA). 
 • It is not known whether patients with CA are at increased risk for 
thromboembolism in general. 
 • Management of thromboembolic events is difficult and treatment 
recommendations for CA patients suffering from thromboembolic events are 
lacking. 
What does this paper add? • Patients with CA are at high risk for arterial and venous thromboembolic 
events. 
 • Frequent, low-dose Fbg replacement appears to be a safe and effective 
treatment option. 
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Figure legends 
Figure 1: Atypical thrombotic lesions along the descending aorta of patient A2 before (A) and 
nine months after (B) orthotopic liver transplantation with major reduction in thrombus volume 
and only minor remnants (see white arrow). 
Figure 2: Clinical course in a patient with congenital afibrinogenemia (A3) 
Figure 3: Contrast enhanced CT angiography of partially floating thrombus of left subclavian 
artery before (A) and five months after (B) intensified prophylactic treatment with fibrinogen 
concentrate (patient A3). Thickness of thrombus decreased markedly and floating component 
resolved. 
Figure 4: Changes of (A) thrombin-antithrombin complex levels (18 observations) and (B) D-
dimers (8 observations) after administration of fibrinogen concentrate in three patients with 
congenital afibrinogenemia 
 
